O’Melveny Represents Belite Bio in US$350 Million Underwritten Public Offering
December 5, 2025
FOR IMMEDIATE RELEASE
SHANGHAI—December 5, 2025—O’Melveny recently represented Belite Bio, Inc (NASDAQ: BLTE) in its follow-on offering of American Depositary Shares (ADSs). The total gross proceeds of the offering was US$350 million, before any exercise of the underwriters’ over-allotment option. The gross proceeds of the offering could reach US$402.5 million if the underwriters exercise the over-allotment option in full. The offering was closed on December 3, 2025.
Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities and Cantor are acting as joint active book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering. Maxim Group LLC and Titan Partners Group, a division of American Capital Partners, are acting as co-managers for the offering.
Based in San Diego, Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic diseases. The company has completed its phase 3 clinical trial for its drug candidate Tinlarebant for Stargardt disease and aims to file relevant new drug application with the U.S. FDA in the first half of 2026.
The O’Melveny team was led by Shanghai corporate partners Portia Ku and Vincent Lin, associate Wuxiao Liang, and legal consultant Chris Wu. Partner Robert Plesnarski advised on SEC related matters. Partner David Ribner advised on OFAC/export control-related representations in the underwriting agreement. Special counsel James Kidder handled FDA-related representations in the underwriting agreement. Counsel Dawn Lim handled tax-related disclosures in the prospectus supplement.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #